West Pharmaceutical Services, Inc. logo

West Pharmaceutical Services, Inc. (WST)

Market Closed
14 Aug, 20:00
NYSE NYSE
$
246. 20
-0.02
-0.01%
After Hours
$
247. 50
+1.3 +0.53%
17.33B Market Cap
49.01 P/E Ratio
0.8% Div Yield
358,778 Volume
7.62 Eps
$ 246.22
Previous Close
Day Range
244 247.23
Year Range
187.43 352.33
Want to track WST and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 69 days
LH vs. WST: Which Stock Is the Better Value Option?

LH vs. WST: Which Stock Is the Better Value Option?

Investors interested in Medical - Dental Supplies stocks are likely familiar with Labcorp (LH) and West Pharmaceutical Services (WST). But which of these two companies is the best option for those looking for undervalued stocks?

Zacks | 7 months ago
Reasons to Hold West Pharmaceutical Stock in Your Portfolio Now

Reasons to Hold West Pharmaceutical Stock in Your Portfolio Now

WST continues to gain momentum due to its strength in the Pharma market unit. However, the decline across its Generics and Biologics business units is concerning.

Zacks | 7 months ago
Reasons to Hold West Pharmaceutical Stock in Your Portfolio Now

Reasons to Hold West Pharmaceutical Stock in Your Portfolio Now

WST continues to gain momentum due to its strength in the Pharma market unit. However, decline across its Generics and Biologics business units is concerning.

Zacks | 8 months ago
West Pharmaceutical Services, Inc. (WST) Q3 2024 Earnings Call Transcript

West Pharmaceutical Services, Inc. (WST) Q3 2024 Earnings Call Transcript

West Pharmaceutical Services, Inc. (NYSE:WST ) Q3 2024 Results Earnings Conference Call October 24, 2024 9:00 AM ET Company Participants John Sweeney - Vice President, Investor Relations Eric Green - Chairman, President and Chief Executive Officer Bernard Birkett - Senior Vice President, Chief Financial Officer Conference Call Participants Jacob Johnson - Stephens Inc. Lawrence Solow - CJS Securities Michael Ryskin - BofA Global Research David Windley - Jefferies Matthew Larew - William Blair & Company Justin Bowers - Deutsche Bank Thomas DeBourcy - Nephron Research Operator Good day and thank you for standing by. Welcome to the Q3 2024 West Pharmaceutical Services Earnings Conference Call.

Seekingalpha | 9 months ago
West Pharmaceutical's Q3 Performance Shows Rising Demand For Syringes, Company Boosts Annual Forecast And Dividend

West Pharmaceutical's Q3 Performance Shows Rising Demand For Syringes, Company Boosts Annual Forecast And Dividend

On Thursday, West Pharmaceutical Services, Inc. WST reported adjusted EPS of $1.85, down from $2.16 a year ago, beating the consensus of $1.50.

Benzinga | 9 months ago
West Pharmaceutical Stock Gains on Q3 Earnings Beat & Raised Guidance

West Pharmaceutical Stock Gains on Q3 Earnings Beat & Raised Guidance

WST's third-quarter results reflect a recovery in the Proprietary Products segment following elevated customer destocking, hurting sales in the second quarter.

Zacks | 9 months ago
West Pharmaceutical Services (WST) Tops Q3 Earnings and Revenue Estimates

West Pharmaceutical Services (WST) Tops Q3 Earnings and Revenue Estimates

West Pharmaceutical Services (WST) came out with quarterly earnings of $1.85 per share, beating the Zacks Consensus Estimate of $1.51 per share. This compares to earnings of $2.16 per share a year ago.

Zacks | 9 months ago
West Pharmaceutical raises annual profit forecast on demand for medical supplies

West Pharmaceutical raises annual profit forecast on demand for medical supplies

West Pharmaceutical Services raised its annual profit forecast on Thursday, after beating Wall Street estimates for quarterly revenue and profit, banking on rising demand for cartridges and syringes used to manufacture injectable therapies.

Reuters | 9 months ago
What's in Store for West Pharmaceutical in Q3 Earnings?

What's in Store for West Pharmaceutical in Q3 Earnings?

WST's third-quarter 2024 results are likely to reflect weakness in its Proprietary Products business. Unfavorable currency movements might have hurt the top and bottom lines.

Zacks | 9 months ago
Earnings Preview: West Pharmaceutical Services (WST) Q3 Earnings Expected to Decline

Earnings Preview: West Pharmaceutical Services (WST) Q3 Earnings Expected to Decline

West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 10 months ago
West Pharmaceutical: Continued Destocking And A High Valuation Post Q2 Results (Rating Maintained)

West Pharmaceutical: Continued Destocking And A High Valuation Post Q2 Results (Rating Maintained)

West Pharmaceutical Q2'24 results missed expectations, with lower revenues and EPS missing guidance, impacted by destocking and poor sales in various segments. Management remains optimistic for the back half of the year, with capital investments to support growth, but cash flow concerns and high valuation pose risks. Despite the recent drop in WST share price, the company's high valuation and uncertain cash flow outlook make it unattractive for investment at this time.

Seekingalpha | 1 year ago
West Pharmaceutical (WST) Misses on Q2 Earnings, Lowers '24 View

West Pharmaceutical (WST) Misses on Q2 Earnings, Lowers '24 View

West Pharmaceutical's (WST) second-quarter results reflect a declining demand for products across its segments amid elevated customer destocking.

Zacks | 1 year ago
Loading...
Load More